Modern Strategies for Treatment of Acute Myocardial Infarction: Significance of Haemostaseological and Rheological Findings
In spite of equivalent clinical efficacy of various thrombolytic agents for the treatment of acute myocardial infarction there is evidence of different drug-depending influences on the haemostatic and fibrinolytic system. In the present study 40 patients with acute myocardial infarction have been investigated. 20 patients received 750,000 and 1.5 mio U streptokinase (SK), respectively, 10 patients 30 mg anisoylated plasminogen streptokinase activator complex (BRL 26921) and 10 patients a combination of 200,000 U urokinase (UK) and 4.5 mio U pro-urokinase (PUK) as a short-term intravenous treatment. Reperfusion of coronary arteries has been achieved in 70 to 100 percent. Major not fatal bleedings occurred in 2 patients. One patient died within 72 hours after beginning of the myocardial infarction. The longest duration of fibrinolytic activity was observed in the BRL 26921 group (half-disappearance time close to 2 h). It was significantly shorter in the SK groups showing a dose-dependency. Plasma concentration of fibrinogen dropped beyond normal levels following SK and BRL 26921, but not under UK/PUK. Plasma viscosity correlated with fibrinogen decrease and displayed a dose-depending relationship with the presence of SK. Haemorheological effects are suggested to be important for the clinical efficacy of thrombolytic therapy in myocardial infarction.
KeywordsAcute Myocardial Infarction Acute Myocardial Infarction Thrombolytic Therapy Fibrinolytic Activity Activate Partial Thromboplastin Time
Unable to display preview. Download preview PDF.
- Fletcher, A. P., Alkjaersig, N., Sherry, S., The clearance of heterologous protein from the circulation of normal and immunized man. J. Clin. Invest., 37:1306–1315.Google Scholar
- GISSI Study group, 1986. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet i, 397–401.Google Scholar
- Köhler, M., Hellstem, P., Doenecke, P., Schwerdt, H., Özbek, C., Miyashita, C., Winter, R., von Blohn, G., Bette, L., Wenzel E., 1987, High-dose systemic streptokinase and acylated streptokinase-plasminogen complex (BRL 26921) in acute myocardial infarction: Alterations of the fibrinolytic system and clearance of fibrinolytic activity. In: Haemostasis, 17:32–39.PubMedGoogle Scholar
- Pindur, G., Sen, S., Köhler, M., Miyashita, C., Heiden, M., Dyckmans, J., Schieffer, H., Wenzel, E., 1988, Parameters of fibrinolysis during combination therapy of acutemyocardial infarction with pro-urokinase/urokinase. Haemostasis, 18:191–192Google Scholar
- Wenzel, E., Kiesewetter, H., Hellstem, P., Radtke, H., Jung, F., Köhler, M., von Blohn G., 1983, Hämorheologische Wirkungen der Fibrinolysetherapie. In: Ehrly, A. M., (Ed.), Therapie mit hämorheologisch wirksamen Substanzen, Verhandlungsbericht 2, Kongreß der DGKH, W. Zuckschwerdt Verlag, München, Bern, Wien, pp. 58–68.Google Scholar
- Wenzel, E., Özbek, C., Schwerdt, H., Dyckmans, J., Blohn, G. V., Miyashita, C., Doenecke, P., Bette L., 1987, Thrombolytic therapy of acute myocardial infarction by intravenous bolus injection of fibrinolytic agents: a critical review of published findings based on new observations, in:Castellion et al. (eds.), Fundamental and clinical fibrinolysis, Elsevier Science Publishers B. V., New York, Amsterdam, London, pp. 205–214.Google Scholar